Inicio > BIGG > Resultado de la búsqueda

    Resultados: 2

    Management of Dyslipidemia for cardiovascular disease risk Reduction: synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline

    O'Malley, Patrick G; Arnold, Michael J; Pharm, Cathy Kelley; Spacek, Lance; Buelt, Andrew; Natarajan, Sundar; Donahue, Mark P; Vagichev, Elena; Ballard-Hernandez, Jennifer; Logan, Amanda; Thomas, Lauren; Ritter, Joan; Neubauer, Brian E; Downs, John R.
    In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations. The guideline panel de...
    Enfermedades Cardiovasculares/prevención & control, Enfermedades Cardiovasculares/diagnóstico, Dislipidemias/prevención & control, Dislipidemias/diagnóstico, Práctica Clínica Basada en la Evidencia, Rehabilitación Cardiaca, Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico
    Texto completo

    Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians

    Qaseem, A; Hopkins, RH Jr; Sweet, D. E; Starkey, M; Shekelle, P.
    Ann. intern. med; 159 (12), 2013
    DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. METHODS: This guideline is based on a systematic evidence review eval...
    Insuficiencia Renal Crónica/diagnóstico, Insuficiencia Renal Crónica/tratamiento farmacológico, Progresión de la Enfermedad, Triaje, Antagonistas de Receptores de Angiotensina/uso terapéutico, Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico, Antihipertensivos/uso terapéutico, Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico, Hipolipemiantes/uso terapéutico, Gemfibrozilo/uso terapéutico, Enfermedades Asintomáticas, Quimioterapia Combinada, Enfoque GRADE
    Texto completo